Macular Ischemia Changes in Patients with Diabetic Macular Edema Treated with Aflibercept and Ranibizumab

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Jun 27

PMID 38928721

Authors

Dimitrios Maris

Anna Dastiridou

Maria Kotoula

Aikaterini Karathanou

Evangelia E Tsironi

Alexandra Bargiota

Sofia Androudi

Affiliations

Soon will be listed here.

Abstract

Τhis study aims to assess changes in the fovea avascular zone (FAZ) in treatment naïve patients receiving aflibercept or ranibizumab injections for diabetic macular edema (DME). Best corrected visual acuity (BCVA) testing, OCT, and OCT-angiography imaging were performed at baseline and 1 month after each injection. Injections of either aflibercept or ranibizumab were administered monthly for 6 consecutive months. FAZ in the superficial (SCP) and the deep capillary plexus (DCP) using OCT angiography was recorded for each visit. Fifty eyes from fifty patients with a mean age of 67.0 ± 10.7 years were included in the study. Twenty-five patients received aflibercept and twenty-five received ranibizumab. BCVA was 40.8 ± 10.0 and increased to 52.1 ± 7.9 ETDRS letters at the last visit ( < 0.001). CRT was 295.6 ± 34.0 at baseline and 247.9 ± 29.7 at the last study visit ( < 0.001). SCP FAZ was 350.6 ± 79.5 μm at baseline and 339.0 ± 71.3 μm after sox monthly injections ( = 0.132). DCP FAZ was 558.6 ± 199.0 μm at baseline and 459.5 ± 156.1 μm after six monthly injections ( < 0.001). There was no effect of the choice of ranibizumab or aflibercept on DCP FAZ change ( = 0.277). In conclusion, treatment with 6 monthly injections of ranibizumab and aflibercept led to an increase in BCVA and a decrease in CRT and DCP FAZ area. Both drugs led to an improvement in DCP ischemia.

References

. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):807-22. View

Czako C, Sandor G, Ecsedy M, Recsan Z, Horvath H, Szepessy Z . Intrasession and Between-Visit Variability of Retinal Vessel Density Values Measured with OCT Angiography in Diabetic Patients. Sci Rep. 2018; 8(1):10598. PMC: 6045633. DOI: 10.1038/s41598-018-28994-7. View

Sorour O, Sabrosa A, Alibhai A, Arya M, Ishibazawa A, Witkin A . Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy. Int Ophthalmol. 2019; 39(10):2361-2371. DOI: 10.1007/s10792-019-01076-x. View

Bhanushali D, Anegondi N, Gadde S, Srinivasan P, Chidambara L, Yadav N . Linking Retinal Microvasculature Features With Severity of Diabetic Retinopathy Using Optical Coherence Tomography Angiography. Invest Ophthalmol Vis Sci. 2016; 57(9):OCT519-25. DOI: 10.1167/iovs.15-18901. View

Abdel-Kader A, Ramsey D, Yussuf W, Mohalhal A, Eldaly M, Elnahry A . Diabetic microaneurysms detected by fluorescein angiography spatially correlate with regions of macular ischemia delineated by optical coherence tomography angiography. Indian J Ophthalmol. 2023; 71(8):3085-3090. PMC: 10538827. DOI: 10.4103/IJO.IJO_3155_22. View

Spaide R . Volume-Rendered Optical Coherence Tomography of Diabetic Retinopathy Pilot Study. Am J Ophthalmol. 2015; 160(6):1200-10. DOI: 10.1016/j.ajo.2015.09.010. View

Carpineto P, Mastropasqua R, Marchini G, Toto L, Di Nicola M, Di Antonio L . Reproducibility and repeatability of foveal avascular zone measurements in healthy subjects by optical coherence tomography angiography. Br J Ophthalmol. 2015; 100(5):671-6. DOI: 10.1136/bjophthalmol-2015-307330. View

Chang Y, Huang Y, Hsu A, Meng P, Lin C, Lai C . Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections. Medicina (Kaunas). 2023; 59(3). PMC: 10053215. DOI: 10.3390/medicina59030629. View

Cennamo G, Romano M, Nicoletti G, Velotti N, de Crecchio G . Optical coherence tomography angiography versus fluorescein angiography in the diagnosis of ischaemic diabetic maculopathy. Acta Ophthalmol. 2016; 95(1):e36-e42. DOI: 10.1111/aos.13159. View

10.

Falavarjani K, Iafe N, Hubschman J, Tsui I, Sadda S, Sarraf D . Optical Coherence Tomography Angiography Analysis of the Foveal Avascular Zone and Macular Vessel Density After Anti-VEGF Therapy in Eyes With Diabetic Macular Edema and Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2017; 58(1):30-34. DOI: 10.1167/iovs.16-20579. View

11.

Tsai W, Thottarath S, Gurudas S, Sen P, Pearce E, Giani A . Correlation of Optical Coherence Tomography Angiography Characteristics with Visual Function to Define Vision-Threatening Diabetic Macular Ischemia. Diagnostics (Basel). 2022; 12(5). PMC: 9139901. DOI: 10.3390/diagnostics12051050. View

12.

Rana V, Agarwal A, Arora A, Bansal R, Dogra M, Bhadada S . Predicting visual outcomes following anti-vascular endothelial growth factor treatment for diabetic macular edema. Indian J Ophthalmol. 2023; 72(Suppl 1):S16-S21. PMC: 10833155. DOI: 10.4103/IJO.IJO_893_23. View

13.

Sim D, Keane P, Zarranz-Ventura J, Fung S, Powner M, Platteau E . The effects of macular ischemia on visual acuity in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2013; 54(3):2353-60. DOI: 10.1167/iovs.12-11103. View

14.

Conti F, Song W, Rodrigues E, Singh R . Changes in retinal and choriocapillaris density in diabetic patients receiving anti-vascular endothelial growth factor treatment using optical coherence tomography angiography. Int J Retina Vitreous. 2019; 5:41. PMC: 6902577. DOI: 10.1186/s40942-019-0192-9. View

15.

Ishibazawa A, Nagaoka T, Takahashi A, Omae T, Tani T, Sogawa K . Optical Coherence Tomography Angiography in Diabetic Retinopathy: A Prospective Pilot Study. Am J Ophthalmol. 2015; 160(1):35-44.e1. DOI: 10.1016/j.ajo.2015.04.021. View

16.

Waheed N, Rosen R, Jia Y, Munk M, Huang D, Fawzi A . Optical coherence tomography angiography in diabetic retinopathy. Prog Retin Eye Res. 2023; 97:101206. PMC: 11268430. DOI: 10.1016/j.preteyeres.2023.101206. View

17.

Abdelshafy M, Abdelshafy A . Correlations Between Optical Coherence Tomography Angiography Parameters and the Visual Acuity in Patients with Diabetic Retinopathy. Clin Ophthalmol. 2020; 14:1107-1115. PMC: 7186882. DOI: 10.2147/OPTH.S248881. View

18.

Hsieh Y, Alam M, Le D, Hsiao C, Yang C, Chao D . OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema. Ophthalmol Retina. 2019; 3(10):826-834. PMC: 6921516. DOI: 10.1016/j.oret.2019.04.027. View

19.

Busch C, Wakabayashi T, Sato T, Fukushima Y, Hara C, Shiraki N . Retinal Microvasculature and Visual Acuity after Intravitreal Aflibercept in Diabetic Macular Edema: An Optical Coherence Tomography Angiography Study. Sci Rep. 2019; 9(1):1561. PMC: 6367399. DOI: 10.1038/s41598-018-38248-1. View

20.

Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C . Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina. 2010; 30(5):781-6. DOI: 10.1097/iae.0b013e3181d2f145. View